Filana Therapeutics Reports Simufilam Findings in TSC2-Deficient Cells
The company said findings published in Cells provide insight into simufilam’s effects on cellular stress responses and mitochondria.
Related stories
Trinity Industries Reports Lower Q3 Earnings, Higher Revenue; Maintains 2026 EPS Outlook
M impact | EQUITY | Oct 29, 2026, 02:13 PM UTC
Jinko Power Q3 Net Profit Falls 95.96% Year Over Year
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
ACAC Investment Agrees to Sell 25% of B&S International Shares
ACAC Investment agrees to sell 25% of B&S International’s issued shares; the headline also names others without identifying them.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
Blue Owl Co-CEO Says Firm Owns Infrastructure Critical to Digital Economy Growth
Blue Owl co-CEO Lipschultz said the company owns physical infrastructure critical to the digital economy's growth.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
Norwegian Cruise Line Raises Full-Year Profit Outlook; Shares Rise
Norwegian Cruise Line shares rose as much as 12.64% after the company raised its full-year profit outlook.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
L3Harris Reports Record $53.2 Billion Backlog After $19.3 Billion in 3Q Orders
L3Harris received $19.3 billion in orders in the third quarter, bringing its backlog to a record $53.2 billion. The report adds to a series of record backlogs among defense contrac
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC